Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-328
Specific or universal ncRNAs
Specific ncRNAs
Class
MicroRNA
Biomarker
Yes
Biomarker application
Prognosis/Treatment
Upstream regulatory factors
Not available
Downstream target
PTEN
Cancer name
Non-Small Cell Lung Cancer
Cancer site
Lung
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
Up
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
Abnormal expression of miR-328 may contribute to cisplatin resistance in NSCLC, and may be considered to be a novel therapeutic target and indicator for the treatment and prognosis of patients with NSCLC treated with cisplatin-based chemotherapy.
Tissue resource
non-small cell lung cancer tissue samples
human non-small cell lung cancer cell lines A549
cisplatin-resistant A549 sublines A549rCDDP
Experiment
qRT-PCR,Western blot,Dual-luciferase reporter assay
Institute
Dezhou People's Hospital
the Cancer Hospital of Peking Union Medical College, Chinese Academy of Medical Sciences
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.